Sagility gains from healthcare cost pressure, cross-selling and CareSeeds integration

Investment View and Growth Thesis

Motilal Oswal Financial Services Limited retained its Buy rating on Sagility in its July 22, 2026 result update and characterises FY27 as a year of growth normalisation after a strong FY26. The broker views US healthcare cost pressure as a structural tailwind for Sagility.

The positive view is supported by new-logo additions, cross-selling opportunities and acquisition synergies. Motilal Oswal expects these factors to support revenue, EBITDA and PAT CAGRs of 19%, 19% and 23%, respectively, over FY26-FY28.

Strong 1QFY27 Financial Performance

Sagility reported a strong 1QFY27, with revenue, EBITDA and PAT ahead of Motilal Oswal's estimates. Constant-currency revenue and organic revenue growth also exceeded expectations.

Management cited an adjusted EBITDA margin of 24.0%.

Operating Trends and FY27 Guidance

Management said reported revenue declined sequentially because seasonal US open-enrolment volumes were absent. However, underlying steady-state organic revenue increased 5.1% quarter on quarter. Seasonal volumes are expected to return in 3QFY27 and 4QFY27, with open-enrolment revenue expected to remain broadly similar to FY26 at about 6% of annual revenue.

Growth is being driven by volumes rather than pricing, including deeper penetration at existing clients and demand for higher-value clinical and care-management services. Sagility signed annual contract value of USD 35.3 million during the quarter. Management said execution capacity is not a constraint; longer sales cycles for large managed-services contracts remain the main limiting factor.

Management reiterated FY27 guidance for low double-digit organic constant-currency revenue growth and an adjusted EBITDA margin of 24-25%, despite the stronger 1QFY27 organic growth. It cited seasonality and deal timing, and expects to provide a narrower outlook after 2QFY27.

Margin Headwinds and Mitigation

Statutory wage revisions in Karnataka and Telangana are expected to create a recurring FY27 EBITDA-margin headwind of about 120 basis points and a one-time exceptional charge of Rs 151 million. The exposure is material because 65-70% of Sagility's workforce is located in these states.

Management plans to offset the impact over 12-18 months through productivity gains and expansion into lower-cost delivery centres. Foreign exchange movements could also support margins. Margin performance could trend towards the upper end of guidance if the final wage impact is lower than estimated.

CareSeeds Acquisition and Cross-Selling Opportunity

Sagility completed the CareSeeds acquisition during the quarter. CareSeeds had FY25 revenue of USD 5.1 million, 95% recurring revenue and a 31.4% EBITDA margin.

• The acquisition added 30 clients, including 26 new client relationships.
• It added a 14-member specialist team and Medicare Advantage quality-management capabilities through the Forecast and Harvest platforms.
• Together, CareSeeds and BroadPath have added more than 55 small and mid-market clients.
• The enlarged client base creates cross-selling potential in quality management, care management, chart abstraction and population-health solutions.

Sagility now serves 109 active client groups and seven of the top 10 US health insurers. Management has not seen a broad-based demand slowdown, as health plans continue to prioritise cost optimisation and operational efficiency.

Estimates, Valuation and Target Price

Motilal Oswal revised its revenue estimates upward while making mixed changes to its PAT estimates.

The broker values Sagility at 19 times FY28E EPS to derive a target price of Rs 57.

Key Risks to the Thesis

• The recurring statutory wage headwind could pressure EBITDA margins.
• Large managed-services contracts could take longer to convert.
• Deal timing and seasonal variability could affect reported growth.
• Acquisition synergies or cross-selling opportunities could fall short of expectations.